GSK TRPV4 blocker program for GSK2798745 and GSK3527497
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- HHSO100201700009C
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- HHSO100201700009C Solicitation number
- Research and Development of TRPV4 Blockade as a Novel Medical Countermeasure for Acute Respiratory Distress Syndrome due to Chlorine Gas Inihilation Award Notice · Posted Sep 25, 2017
- Last date to order 100% complete
- IDV ceiling
- $58,002,880.21
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract, awarded by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, is for the development of the pharmaceutical compound GSK2798745 for the treatment of pulmonary congestion in patients with heart failure. The single-award contract has a ceiling value of $58,002,880.21 and a period of performance through December 31, 2023. It was awarded to the prime contractor Glaxosmithkline, LLC, a pharmaceutical company that provides a range of vaccines, antivirals, and other medical countermeasures to federal agencies.
The contract aims to support the clinical development of GSK2798745, a TRPV4 blocker, as well as the related compound GSK3527497, through activities such as preclinical studies, clinical trials, and manufacturing. Glaxosmithkline has also received federal grants and subcontracts for other pharmaceutical research and development efforts, including the clinical testing of a small molecule drug to treat urinary tract infections. This contract supports the government's medical preparedness and response capabilities by advancing the development of a potential new treatment for a condition affecting heart failure patients.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$3,737,901 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $17,061,805 |
Show all 20
Quick answers
Who was awarded contract HHSO100201700009C?
HHSO100201700009C was awarded to Glaxosmithkline, LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 25, 2017.
How much is contract HHSO100201700009C worth?
HHSO100201700009C's own ceiling is $58,002,880.
Who can order from contract HHSO100201700009C?
HHSO100201700009C is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract HHSO100201700009C competed?
The extent of competition for HHSO100201700009C was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV